PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32842143-9	2021	In order to explore this concept, we performed a c-Maf-recognition element-driven luciferase-based screen against FDA-approved drugs and natural products, from which the generic cardiac glycoside lanatoside C (LanC) is found to prevent c-Maf de-ubiquitination and induces its degradation by disrupting the interaction of Otub1 and c-Maf.	lanatoside C	210-214	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	49-54
32842143-9	2021	In order to explore this concept, we performed a c-Maf-recognition element-driven luciferase-based screen against FDA-approved drugs and natural products, from which the generic cardiac glycoside lanatoside C (LanC) is found to prevent c-Maf de-ubiquitination and induces its degradation by disrupting the interaction of Otub1 and c-Maf.	lanatoside C	210-214	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	236-241
32842143-9	2021	In order to explore this concept, we performed a c-Maf-recognition element-driven luciferase-based screen against FDA-approved drugs and natural products, from which the generic cardiac glycoside lanatoside C (LanC) is found to prevent c-Maf de-ubiquitination and induces its degradation by disrupting the interaction of Otub1 and c-Maf.	lanatoside C	210-214	OTU domain, ubiquitin aldehyde binding 1	Mus musculus	321-326
32842143-9	2021	In order to explore this concept, we performed a c-Maf-recognition element-driven luciferase-based screen against FDA-approved drugs and natural products, from which the generic cardiac glycoside lanatoside C (LanC) is found to prevent c-Maf de-ubiquitination and induces its degradation by disrupting the interaction of Otub1 and c-Maf.	lanatoside C	210-214	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	236-241
32842143-10	2021	Consequently, LanC inhibits c-Maf transcriptional activity, induces c-Maf-expressing MM cell apoptosis, and suppresses MM growth and prolongs overall survival of model mice but without apparent toxicity.	lanatoside C	14-18	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	28-33
32842143-10	2021	Consequently, LanC inhibits c-Maf transcriptional activity, induces c-Maf-expressing MM cell apoptosis, and suppresses MM growth and prolongs overall survival of model mice but without apparent toxicity.	lanatoside C	14-18	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	68-73
31783627-0	2019	Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR Signaling Pathways.	lanatoside C	0-12	AKT serine/threonine kinase 1	Homo sapiens	123-126
31783627-0	2019	Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR Signaling Pathways.	lanatoside C	0-12	mechanistic target of rapamycin kinase	Homo sapiens	127-131
30854687-8	2019	In addition, TGF-beta1-induced migration in lung fibroblasts was also impeded after lanatoside C treatment.	lanatoside C	84-96	transforming growth factor, beta 1	Mus musculus	13-22
31392779-3	2019	Herein, we evaluated lanatoside c and digoxin, both of which are widely used cardiac glycosides (CGs), for their ability to sensitize human hepatocellular carcinoma cells (Huh-7 and HepG2) through TRAIL-induced apoptosis.	lanatoside C	21-33	TNF superfamily member 10	Homo sapiens	197-202
29475060-0	2018	Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/beta-catenin/c-Myc signaling pathway in human gastric cancer cell.	lanatoside C	0-12	catenin beta 1	Homo sapiens	87-99
29475060-0	2018	Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/beta-catenin/c-Myc signaling pathway in human gastric cancer cell.	lanatoside C	0-12	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	100-105
29475060-4	2018	Lanatoside C inhibited Wnt/beta-catenin signaling with downregulation of c-Myc, while overexpression of c-Myc reversed the anti-tumor effect of lanatoside C, confirming that c-Myc is a key drug target of lanatoside C. Furthermore, we discovered that lanatoside C prompted c-Myc degradation in proteasome-ubiquitin pathway with attenuating the binding of USP28 to c-Myc.	lanatoside C	0-12	catenin beta 1	Homo sapiens	27-39
29475060-2	2018	Our studies revealed that lanatoside C, a FDA-approved cardiac glycoside, had an anti-proliferation effect on different human cancer cell lines (MKN-45; SGC-7901; HN4; MCF-7; HepG2) and gastric cell lines MKN-45 and SGC-7901 were the most sensitive cell lines to lanatoside C. MKN-45 cells treated with lanatoside C showed cell cycle arrest at G2/M phase and inhibition of cell migration.	lanatoside C	26-38	MT-RNR2 like 4 (pseudogene)	Homo sapiens	163-166
29475060-4	2018	Lanatoside C inhibited Wnt/beta-catenin signaling with downregulation of c-Myc, while overexpression of c-Myc reversed the anti-tumor effect of lanatoside C, confirming that c-Myc is a key drug target of lanatoside C. Furthermore, we discovered that lanatoside C prompted c-Myc degradation in proteasome-ubiquitin pathway with attenuating the binding of USP28 to c-Myc.	lanatoside C	0-12	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	73-78
29475060-4	2018	Lanatoside C inhibited Wnt/beta-catenin signaling with downregulation of c-Myc, while overexpression of c-Myc reversed the anti-tumor effect of lanatoside C, confirming that c-Myc is a key drug target of lanatoside C. Furthermore, we discovered that lanatoside C prompted c-Myc degradation in proteasome-ubiquitin pathway with attenuating the binding of USP28 to c-Myc.	lanatoside C	144-156	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
29475060-4	2018	Lanatoside C inhibited Wnt/beta-catenin signaling with downregulation of c-Myc, while overexpression of c-Myc reversed the anti-tumor effect of lanatoside C, confirming that c-Myc is a key drug target of lanatoside C. Furthermore, we discovered that lanatoside C prompted c-Myc degradation in proteasome-ubiquitin pathway with attenuating the binding of USP28 to c-Myc.	lanatoside C	144-156	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
29475060-4	2018	Lanatoside C inhibited Wnt/beta-catenin signaling with downregulation of c-Myc, while overexpression of c-Myc reversed the anti-tumor effect of lanatoside C, confirming that c-Myc is a key drug target of lanatoside C. Furthermore, we discovered that lanatoside C prompted c-Myc degradation in proteasome-ubiquitin pathway with attenuating the binding of USP28 to c-Myc.	lanatoside C	144-156	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
28680263-12	2017	Cedilanid inhibited the expression of HIF-1alpha and VEGF in mice treated with hyperoxia.	lanatoside C	0-9	hypoxia inducible factor 1, alpha subunit	Mus musculus	38-48
29475060-4	2018	Lanatoside C inhibited Wnt/beta-catenin signaling with downregulation of c-Myc, while overexpression of c-Myc reversed the anti-tumor effect of lanatoside C, confirming that c-Myc is a key drug target of lanatoside C. Furthermore, we discovered that lanatoside C prompted c-Myc degradation in proteasome-ubiquitin pathway with attenuating the binding of USP28 to c-Myc.	lanatoside C	144-156	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
29475060-4	2018	Lanatoside C inhibited Wnt/beta-catenin signaling with downregulation of c-Myc, while overexpression of c-Myc reversed the anti-tumor effect of lanatoside C, confirming that c-Myc is a key drug target of lanatoside C. Furthermore, we discovered that lanatoside C prompted c-Myc degradation in proteasome-ubiquitin pathway with attenuating the binding of USP28 to c-Myc.	lanatoside C	204-216	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
29475060-4	2018	Lanatoside C inhibited Wnt/beta-catenin signaling with downregulation of c-Myc, while overexpression of c-Myc reversed the anti-tumor effect of lanatoside C, confirming that c-Myc is a key drug target of lanatoside C. Furthermore, we discovered that lanatoside C prompted c-Myc degradation in proteasome-ubiquitin pathway with attenuating the binding of USP28 to c-Myc.	lanatoside C	204-216	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
29475060-4	2018	Lanatoside C inhibited Wnt/beta-catenin signaling with downregulation of c-Myc, while overexpression of c-Myc reversed the anti-tumor effect of lanatoside C, confirming that c-Myc is a key drug target of lanatoside C. Furthermore, we discovered that lanatoside C prompted c-Myc degradation in proteasome-ubiquitin pathway with attenuating the binding of USP28 to c-Myc.	lanatoside C	204-216	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
29475060-4	2018	Lanatoside C inhibited Wnt/beta-catenin signaling with downregulation of c-Myc, while overexpression of c-Myc reversed the anti-tumor effect of lanatoside C, confirming that c-Myc is a key drug target of lanatoside C. Furthermore, we discovered that lanatoside C prompted c-Myc degradation in proteasome-ubiquitin pathway with attenuating the binding of USP28 to c-Myc.	lanatoside C	204-216	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
28680263-12	2017	Cedilanid inhibited the expression of HIF-1alpha and VEGF in mice treated with hyperoxia.	lanatoside C	0-9	vascular endothelial growth factor A	Mus musculus	53-57
26902406-12	2016	Lanatoside C was further shown to induce oxidative stress and alter ERK and Akt pathways.	lanatoside C	0-12	mitogen-activated protein kinase 1	Homo sapiens	68-71
26756216-7	2016	Recruitment of 53BP1 to damaged DNA, a critical initiation step for DNA damage repair signaling, was significantly suppressed in lanatoside C-treated HCT116 cells.	lanatoside C	129-141	tumor protein p53 binding protein 1	Homo sapiens	15-20
26902406-15	2016	In this study apoptosis induction by Lanatoside C was characterized through ROS altered ERK and Akt pathways in both PTEN adequate epithelial and deficient mesenchymal liver cancer cells.	lanatoside C	37-49	AKT serine/threonine kinase 1	Homo sapiens	96-99
28387249-6	2017	Inhibition of PKCdelta reversed lanatoside C-induced MMP loss and apoptosis, confirming that lanatoside C caused apoptosis through PKCdelta activation.	lanatoside C	32-44	protein kinase C delta	Homo sapiens	14-22
28387249-6	2017	Inhibition of PKCdelta reversed lanatoside C-induced MMP loss and apoptosis, confirming that lanatoside C caused apoptosis through PKCdelta activation.	lanatoside C	93-105	protein kinase C delta	Homo sapiens	131-139
26821916-4	2016	Lanatoside C dose-dependently aggravated the development of atherosclerosis in the ApoE(-/-) mice compared with the vehicle control group.	lanatoside C	0-12	apolipoprotein E	Mus musculus	83-87
26821916-6	2016	Meanwhile, the effects of lanatoside C were abolished using small interfering RNA (siRNA) inhibition of peroxisome proliferator-activated receptors beta/delta (PPARbeta/delta).	lanatoside C	26-38	peroxisome proliferator activator receptor delta	Mus musculus	160-168
26902406-12	2016	Lanatoside C was further shown to induce oxidative stress and alter ERK and Akt pathways.	lanatoside C	0-12	AKT serine/threonine kinase 1	Homo sapiens	76-79
26902406-15	2016	In this study apoptosis induction by Lanatoside C was characterized through ROS altered ERK and Akt pathways in both PTEN adequate epithelial and deficient mesenchymal liver cancer cells.	lanatoside C	37-49	phosphatase and tensin homolog	Homo sapiens	117-121
26902406-15	2016	In this study apoptosis induction by Lanatoside C was characterized through ROS altered ERK and Akt pathways in both PTEN adequate epithelial and deficient mesenchymal liver cancer cells.	lanatoside C	37-49	mitogen-activated protein kinase 1	Homo sapiens	88-91
24801379-5	2014	This study demonstrates the potential of systemic injection of NSCs to deliver anticancer agents, such as TRAIL, which yields glioma regression when combined with Lan C.	lanatoside C	163-168	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	106-111
34466152-0	2021	Lanatoside C inhibits human cervical cancer cell proliferation and induces cell apoptosis by a reduction of the JAK2/STAT6/SOCS2 signaling pathway.	lanatoside C	0-12	Janus kinase 2	Homo sapiens	112-116
21757445-0	2011	Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway.	lanatoside C	0-12	TNF superfamily member 10	Homo sapiens	46-101
21757445-2	2011	We have identified lanatoside C as a sensitizer of GBM cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death partly by upregulation of the death receptor 5.	lanatoside C	19-31	TNF superfamily member 10	Homo sapiens	64-119
21757445-2	2011	We have identified lanatoside C as a sensitizer of GBM cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death partly by upregulation of the death receptor 5.	lanatoside C	19-31	TNF superfamily member 10	Homo sapiens	121-126
21757445-2	2011	We have identified lanatoside C as a sensitizer of GBM cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death partly by upregulation of the death receptor 5.	lanatoside C	19-31	TNF receptor superfamily member 10b	Homo sapiens	177-193
21757445-3	2011	We show that lanatoside C sensitizes GBM cells to TRAIL-induced apoptosis in a GBM xenograft model in vivo.	lanatoside C	13-25	TNF superfamily member 10	Homo sapiens	50-55
21757445-6	2011	In conclusion, lanatoside C sensitizes GBM cells to TRAIL-induced cell death and mitigates apoptosis resistance of glioblastoma cells by inducing an alternative cell death pathway.	lanatoside C	15-27	TNF superfamily member 10	Homo sapiens	52-57
34768108-6	2021	Using the FDA-approved CG compound Lanatoside C (LanC) and human pancreatic cancer cell lines as model systems, we discovered that LanC preferably suppressed ER stress induction of GRP78 and to a lesser extent GRP94.	lanatoside C	35-47	heat shock protein family A (Hsp70) member 5	Homo sapiens	181-186
34768108-6	2021	Using the FDA-approved CG compound Lanatoside C (LanC) and human pancreatic cancer cell lines as model systems, we discovered that LanC preferably suppressed ER stress induction of GRP78 and to a lesser extent GRP94.	lanatoside C	35-47	heat shock protein 90 beta family member 1	Homo sapiens	210-215
34768108-6	2021	Using the FDA-approved CG compound Lanatoside C (LanC) and human pancreatic cancer cell lines as model systems, we discovered that LanC preferably suppressed ER stress induction of GRP78 and to a lesser extent GRP94.	lanatoside C	49-53	heat shock protein family A (Hsp70) member 5	Homo sapiens	181-186
34768108-6	2021	Using the FDA-approved CG compound Lanatoside C (LanC) and human pancreatic cancer cell lines as model systems, we discovered that LanC preferably suppressed ER stress induction of GRP78 and to a lesser extent GRP94.	lanatoside C	131-135	heat shock protein family A (Hsp70) member 5	Homo sapiens	181-186
34466152-7	2021	Taken together, the results of the present study suggest that lanatoside C suppresses cell proliferation and induces cell apoptosis by inhibiting JAK2-STAT6 signaling, indicating that lanatoside C is a promising agent for the treatment of cervical cancer.	lanatoside C	184-196	signal transducer and activator of transcription 6	Homo sapiens	151-156
19149943-10	2008	Compared with those in burn control group, the parameters of myocardiac mechanics and blood flow of liver, kidney, intestine (240 +/- 49, 239 +/- 75, 194 +/- 55 PU, respectively) in cedilanid + enalaprilat group increased significantly (P < 0.05), and the serum contents of cTnI, TBA, beta2-MG, DAO (3.43 +/- 0.21 microg/L, 47 +/- 8 micromol/L, 2.01 +/- 0.16 mg/L, 1.17 +/- 0.15 kU/L, respectively) were decreased (P < 0.05).	lanatoside C	182-191	troponin I3, cardiac type	Rattus norvegicus	277-281
34768108-0	2021	Suppression of ER-stress induction of GRP78 as an anti-neoplastic mechanism of the cardiac glycoside Lanatoside C in pancreatic cancer: Lanatoside C suppresses GRP78 stress induction.	lanatoside C	136-148	heat shock protein family A (Hsp70) member 5	Homo sapiens	38-43
34768108-0	2021	Suppression of ER-stress induction of GRP78 as an anti-neoplastic mechanism of the cardiac glycoside Lanatoside C in pancreatic cancer: Lanatoside C suppresses GRP78 stress induction.	lanatoside C	136-148	heat shock protein family A (Hsp70) member 5	Homo sapiens	160-165
34466152-0	2021	Lanatoside C inhibits human cervical cancer cell proliferation and induces cell apoptosis by a reduction of the JAK2/STAT6/SOCS2 signaling pathway.	lanatoside C	0-12	signal transducer and activator of transcription 6	Homo sapiens	117-122
34466152-0	2021	Lanatoside C inhibits human cervical cancer cell proliferation and induces cell apoptosis by a reduction of the JAK2/STAT6/SOCS2 signaling pathway.	lanatoside C	0-12	suppressor of cytokine signaling 2	Homo sapiens	123-128
34466152-6	2021	Furthermore, lanatoside C inhibited the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 6 (STAT6), while inducing the expression of suppressor of cytokine signaling 2, a negative regulator of JAK2-STAT6 signaling.	lanatoside C	13-25	Janus kinase 2	Homo sapiens	59-73
34466152-6	2021	Furthermore, lanatoside C inhibited the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 6 (STAT6), while inducing the expression of suppressor of cytokine signaling 2, a negative regulator of JAK2-STAT6 signaling.	lanatoside C	13-25	Janus kinase 2	Homo sapiens	75-79
34466152-6	2021	Furthermore, lanatoside C inhibited the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 6 (STAT6), while inducing the expression of suppressor of cytokine signaling 2, a negative regulator of JAK2-STAT6 signaling.	lanatoside C	13-25	signal transducer and activator of transcription 6	Homo sapiens	85-135
34466152-6	2021	Furthermore, lanatoside C inhibited the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 6 (STAT6), while inducing the expression of suppressor of cytokine signaling 2, a negative regulator of JAK2-STAT6 signaling.	lanatoside C	13-25	signal transducer and activator of transcription 6	Homo sapiens	137-142
34466152-6	2021	Furthermore, lanatoside C inhibited the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 6 (STAT6), while inducing the expression of suppressor of cytokine signaling 2, a negative regulator of JAK2-STAT6 signaling.	lanatoside C	13-25	suppressor of cytokine signaling 2	Homo sapiens	178-212
34466152-6	2021	Furthermore, lanatoside C inhibited the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 6 (STAT6), while inducing the expression of suppressor of cytokine signaling 2, a negative regulator of JAK2-STAT6 signaling.	lanatoside C	13-25	Janus kinase 2	Homo sapiens	238-242
34466152-6	2021	Furthermore, lanatoside C inhibited the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 6 (STAT6), while inducing the expression of suppressor of cytokine signaling 2, a negative regulator of JAK2-STAT6 signaling.	lanatoside C	13-25	signal transducer and activator of transcription 6	Homo sapiens	243-248
34466152-7	2021	Taken together, the results of the present study suggest that lanatoside C suppresses cell proliferation and induces cell apoptosis by inhibiting JAK2-STAT6 signaling, indicating that lanatoside C is a promising agent for the treatment of cervical cancer.	lanatoside C	62-74	Janus kinase 2	Homo sapiens	146-150
34466152-7	2021	Taken together, the results of the present study suggest that lanatoside C suppresses cell proliferation and induces cell apoptosis by inhibiting JAK2-STAT6 signaling, indicating that lanatoside C is a promising agent for the treatment of cervical cancer.	lanatoside C	62-74	signal transducer and activator of transcription 6	Homo sapiens	151-156
34466152-7	2021	Taken together, the results of the present study suggest that lanatoside C suppresses cell proliferation and induces cell apoptosis by inhibiting JAK2-STAT6 signaling, indicating that lanatoside C is a promising agent for the treatment of cervical cancer.	lanatoside C	184-196	Janus kinase 2	Homo sapiens	146-150
34145369-0	2021	Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model.	lanatoside C	36-48	erb-b2 receptor tyrosine kinase 2	Mus musculus	82-86
34145369-2	2021	In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal growth factor receptor 2 (HER2) positive tumor progression in NCI-N87 xenograft model.	lanatoside C	104-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-175
34145369-2	2021	In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal growth factor receptor 2 (HER2) positive tumor progression in NCI-N87 xenograft model.	lanatoside C	104-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-181
34145369-4	2021	Biodistribution studies using 131I-trastuzumab or combination of 131I-trastuzumab and lanatoside C showed tumor uptake in BALB/c nude mice bearing HER2 positive NCI-N87 tumor xenograft model.	lanatoside C	86-98	erb-b2 receptor tyrosine kinase 2	Mus musculus	147-151
34145369-8	2021	Taken together, our data suggest that combination of 131I-trastuzumab and lanatoside C might be a potential synergistic treatment for radioimmunotherapy to control the HER2 positive tumor.	lanatoside C	74-86	erb-b2 receptor tyrosine kinase 2	Mus musculus	168-172